Search
Baxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalIt targets aldosterone excess, a primary underlying driver of treatment resistance and organ damage in cardiovascular diseases [A275512, A275515]. … On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189].
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: (+)-(r)-n-(4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide, N-((8r)-5,6,7,8-tetrahydro-4-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-8-isoquinolinyl)propanamideLenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigational[L42995] On December 22, 2022, it was also approved by the FDA.[L44473] … [A244170, A244175] Lenacapavir is a first-in-class capsid inhibitor that demonstrates picomolar HIV-1 inhibition as a monotherapy _in vitro_, little to no cross-resistance with existing antiretroviral
Synonyms: N-((1S)-1-(3-(4-CHLORO-3-(METHANESULFONAMIDO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-(METHANESULFONYL)-3-METHYLBUT-1-YN-1-YL)PYRIDIN-2-YL)-2-(3,5- DIFLUOROPHENYL)ETHYL)-2-((3BS,4AR)-5,5-DIFLUORO, 1H-CYCLOPROPA(3,4)CYCLOPENTA(1,2-C)PYRAZOLE, N-((1S)-1-(3-(4-CHLORO-3-((METHYLSULFONYL)AMINO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-METHYL-3-(METHYLSULFONYL)-1-BUTYN-1-YL)-2-PYRIDINYL)-2-(3,5-Categories: Heterocyclic Compounds, 2-Ring, P-glycoprotein substratesN-[2-(1-Formyl-2-Methyl-Propyl)-1-(4-Piperidin-1-Yl-but-2-Enoyl)-Pyrrolidin-3-Yl]-Methanesulfonamide
go.drugbank.com/drugs/DB03890ExperimentalSynonyms: N-[2-(1-Formyl-2-Methyl-Propyl)-1-(4-Piperidin-1-Yl-but-2-Enoyl)-Pyrrolidin-3-Yl]-MethanesulfonamideN-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE
go.drugbank.com/drugs/DB07790ExperimentalSynonyms: N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE(2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
go.drugbank.com/drugs/DB08463ExperimentalSynonyms: (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol4-(2-Amino-Ethoxy)-2-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Amino]-but-3-Enoic Acid
go.drugbank.com/drugs/DB03287ExperimentalSynonyms: 4-(2-Amino-Ethoxy)-2-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Amino]-but-3-Enoic AcidMianserin
go.drugbank.com/drugs/DB06148ApprovedWithdrawnA tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of [mirtazapine].
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 3-RingSynonyms: 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepineProcainamide
go.drugbank.com/drugs/DB01035ApprovedA derivative of procaine with less CNS action.
Synonyms: p-Amino-N-(2-diethylaminoethyl)benzamide, p-Aminobenzoic diethylaminoethylamideCategories: MATE 2 Substrates, MATE 2 Substrates with a Narrow Therapeutic IndexDuloxetine
go.drugbank.com/drugs/DB00476ApprovedInvestigationalDuloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. … [L6454] It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence.
Synonyms: (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine, (S)-duloxetineCategories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates(Z)-3-BENZYL-5-(2-HYDROXY-3-NITROBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE
go.drugbank.com/drugs/DB07838ExperimentalSynonyms: (Z)-3-BENZYL-5-(2-HYDROXY-3-NITROBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE